RNA
Live chart
What they do
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
For information only · Important disclosures
Grades vs sector
No sector grades for RNA yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Systematic Models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-13 | -0.64 | -1.18 | -84.4% |
| 2026-05-14 | -1.05 | -0.97 | +7.6% |
| 2026-02-23 | -1.26 | -1.59 | -26.4% |
| 2025-11-10 | -1.10 | -1.27 | -15.3% |
| 2025-08-07 | -0.96 | -1.21 | -26.3% |
| 2025-05-08 | -0.88 | -0.90 | -2.2% |
| 2025-02-27 | -0.78 | -0.80 | -2.5% |
| 2024-11-07 | -0.72 | -0.65 | +9.5% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $3.0M | -21.9% |
| 2026-03-31 | $19.6M | – |
| 2025-12-31 | $859.0K | – |
| 2025-09-30 | $12.3M | – |
| 2025-06-30 | $3.8M | – |
Rating changes
Third-party analyst actions, not Coteau's views. All rating changes
Stats refreshed 2026-10-22 21:21:39 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app
Beta 0.9 · Oct 21, 2026